Table 2 Comparisons of Drug Outcome for Studies Included in the Meta-Analysis
From: Review of Desloratadine Data Using the ARIA Guidelines
Outcome | Comparison | Studies (n) | Patients (n) | I 2 (%) | Effect | 95% CI | P |
|---|---|---|---|---|---|---|---|
Total symptom score | DL-placebo | 11 | 3108 | 99.3 | -1.63 | -2.75 to -0.51 | 0.004 |
| Â | DL-LCZ | 3 | 86 | 59.9 | 0.54 | -0.20 to 1.27 | 0.15 |
Total nasal symptom score | DL-placebo | 7 | 2883 | 86.8 | -0.66 | -0.91 to -0.42 | <0.001 |
Nasal airflow | DL-placebo | 5 | 438 | 18.1 | 0.32 | 0.10 to 0.55 | 0.005 |
Nasal eosinophils | DL-placebo | 4 | 133 | 89.7 | -1.28 | -2.57 to 0.01 | 0.05 |
| Â | DL-LCZ | 3 | 88 | 93 | 1.37 | -0.74 to 3.49 | 0.20 |
Nasal interleukin-4 | DL-placebo | 3 | 88 | 94.5 | -2.18 | -5.01 to 0.64 | 0.13 |
| Â | DL-LCZ | 3 | 88 | 90.2 | -0.66 | -0.91 to -0.42 | 0.08 |
LCZ, levocetirizine; I2, I-square statistic; DL, desloratadine. | |||||||